Hemispherx Reports 2018 Third Quarter and First Nine Months Financial Results

by Barry101 | Nov 15, 2018 | Press Release

OCALA, Fla., Nov. 15, 2018 — Hemispherx Biopharma, Inc. (NYSE American:  HEB) announces financial results for the three and nine months ended September 30, 2018, and provides a business update.Highlights of the 2018 third quarter include:Successful animal...

Hemispherx’s Presentation at the Dawson James Securities 4th Annual Small Cap Growth Conference to Be Livestreamed

by Barry101 | Oct 29, 2018 | Press Release

OCALA, Fla., Oct. 29, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, will livestream CEO Thomas K. Equels’ presentation at the...

Hemispherx’s Presentation at the Dawson James Securities 4th Annual Small Cap Growth Conference to Be Livestreamed

by Barry101 | Oct 29, 2018 | Press Release

OCALA, Fla., Oct. 29, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, will livestream CEO Thomas K. Equels’ presentation at the...

Hemispherx to Present at the Dawson James Securities 4th Annual Small Cap Growth Conference

by Barry101 | Oct 24, 2018 | Press Release

ORLANDO, Fla., Oct. 24, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced that CEO Thomas K. Equels will present at the...

Hemispherx to Present at the Dawson James Securities 4th Annual Small Cap Growth Conference

by Barry101 | Oct 24, 2018 | Press Release

ORLANDO, Fla., Oct. 24, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced that CEO Thomas K. Equels will present at the...

Hemispherx Outlines Ampligen Combination Therapy Clinical Study Strategy for the Treatment of Multiple Cancers in Letter to Stockholders

by Barry101 | Oct 22, 2018 | Press Release

ORLANDO, Fla., Oct. 22, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB) announces that Thomas K. Equels, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business update. The full text of the Letter, which has also...